Logo

Roche and Structural Genomix Pen Drug Development Deal

Sep 09, 2004

NEW YORK, Sept. 9 (GenomeWeb News) - Roche and Structural Genomix today said they would collaborate on a project to discover new anti-viral therapeutics. SGX will discover small molecule inhibitors that Roche will develop and commercialize worldwide.

 

Under the terms of the agreement, SGX will receive from Roche an upfront payment, research funding, and milestone payments during product development, as well as royalties from product sales.

 

Stephen Burley, chief scientific officer of SGX, said in a statement that the move was consistent with the company's strategy to use its FAST technology to discover drug candidates for its partners, as well as oncology candidates for SGX to develop.

 

SGX's FAST technology identifies drug candidates with a fragment-based approach using high-throughput protein crystallography, computational chemistry and parallel synthesis.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.